Abstract
The efficacy of immune checkpoint inhibitors (ICI) in ALK-positive non–small-cell lung cancer (NSCLC) is inconclusive as a result of limited data. We conducted a real-world analysis in 83 patients with ALK+ advanced NSCLC treated with ICI. The median real-world progression-free survival was 2.34 months from initiation of ICI therapy. The real-world effectiveness of ICI in ALK+ NSCLC patients was limited.
Original language | English (US) |
---|---|
Pages (from-to) | 49-57 |
Number of pages | 9 |
Journal | Clinical Lung Cancer |
Volume | 22 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2021 |
Externally published | Yes |
Keywords
- Cancer genomics
- Immune checkpoint inhibitor
- Next-generation sequencing
- Resistance
- Targeted therapy
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research